RxDoctor Payments Data

Alicia Attanasio-Shnitser, DPM

Foot & Ankle Surgery · New York, NYNPI 1629415492

Payments from drug & device makers

$1,099in general payments, 2019–2025

Across 19 payments — averaging $57.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$841
  • Orthofix Medical, Inc.$78
  • Treace Medical Concepts, Inc.$50
  • Smith+Nephew$25
  • Bioventus LLC$18
  • Paratek Pharmaceuticals, Inc.$17
  • plus $69 from 5 others

What the payments were for

  • Food & beverage$1,099100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,099 in reported general payments places this provider in the 35th percentile of 652 foot & ankle surgery providers in New York.

See all foot & ankle surgery providers in New York

Medicare billing

Part B allowed, 2024
$208,886
Medicare patients
383
Services billed
2,416

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole14$14,399
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip53$990
Imiquimod20$444
Diclofenac Sodium11$439
Ciclopirox15$282
Silver Sulfadiazine13$207
SsdSilver Sulfadiazine11$150
Cephalexin25$116
Gabapentin20$108
Terbinafine Hcl19$75
Meloxicam28$29

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$13$14,39914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 652 foot & ankle surgery providers in New York.

Other foot & ankle surgery in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →